H. Lundbeck said it plans to purchase Chelsea Therapeutics for as much as $658 million. The acquisition, expected to be finalized next quarter, will give Lundbeck access to Chelsea's investigational neurologic disorder treatments and its FDA-approved neurogenic orthostatic hypotension drug Northera. The firms expect Northera to enter the market in the second half of 2014.

Related Summaries